Earnings Call Intelligence Subscribe
Home › Call Sheets › JNJ › Q1'26
Call sheet · Q1'26

Johnson & Johnson (JNJ)

Q1'26 earnings call · held April 14, 2026 · compared with the Q4'25 call · management-credibility review
11/12
Disclosure score
5 medium, 2 low flags
Financial quality
Bottom line
The real story is INLEXZO quietly exploding with 90% weekly growth post-J-code while everyone focuses on ICOTYDE's solid launch. JNJ is already delivering double-digit growth ex-STELARA, making the 'end of decade' language just conservative positioning. But the binding constraint is margin pressure from heavy launch investments and tariffs - they're spending growth before they earn it. As Duato said, ICOTYDE could be 'one of our largest products ever,' which in JNJ terms means $10B+. My view changes if Q2 free cash flow doesn't recover or if ICOTYDE prescription growth stalls after the initial enthusiasm.

The 30-second version

  • ICOTYDE launches day one ready while INLEXZO quietly explodes post-J-code approval
  • Double-digit growth story is already happening if you strip out STELARA
  • Margins compressed 390bps on MedTech, 280bps on Pharma despite strong top-line

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$24.6B (+7.1% YoY)$24.1B (+6.4% YoY)Deceleration despite easier STELARA comps
Adjusted EPS$2.46 (+21.5% YoY)$2.70 (-2.5% YoY)Sharp reversal from strong growth to decline
Innovative Medicine Revenue$15.8B (+7.9% YoY)$15.4B (+7.4% YoY)Slight deceleration but still solid
Innovative Medicine Margin36.3%39.7%Actually improved 340bps vs prior quarter
MedTech Revenue$8.8B (+5.8% YoY)$8.6B (+4.6% YoY)Deceleration of 120bps
MedTech Margin17.4%22.3%Actually improved 490bps vs prior quarter
DARZALEX Sales~$1B (+24.1% YoY)~$1B (+17.8% YoY)Growth rate cooling but still strong
TREMFYA Sales~$1.25B (+65.4% YoY)~$1.3B (+63.8% YoY)Slight deceleration from torrid pace
CARVYKTI Sales$555M (+63.2% YoY)~$600M (+57.4% YoY)Growth moderating but base expanding
Free Cash FlowNot disclosed Q4$1.5B (run rate ~$6B)Well below $21B annual guidance

Accountability tracked

8 new promises made6 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full JNJ Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.